Evidence map›Paper›PMID 41835784›Full record

ArticleCureus2026

Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case Report.

Tomoyuki Ikeuchi, Mitsuhiro Yamamoto, Hirokazu Toge, Naoto Burioka, Akira Yamasaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tomoyuki IkeuchiDepartment of Respiratory Medicine, National Hospital Organization (NHO) Yonago Medical Center, Yonago, JPN.
Mitsuhiro YamamotoDepartment of Respiratory Medicine, National Hospital Organization (NHO) Yonago Medical Center, Yonago, JPN.
Hirokazu TogeDepartment of Respiratory Medicine, National Hospital Organization (NHO) Yonago Medical Center, Yonago, JPN.
Naoto BuriokaFaculty of Medicine, Tottori University, Yonago, JPN.
Akira YamasakiDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tarlatamab is a bispecific T-cell engager immunotherapy that targets delta-like ligand 3 and CD3. We report a case of pseudoprogression (PsPD) in a patient with small-cell lung cancer treated with tarlatamab. Due to its mechanism, tarlatamab is known to induce T-cell infiltration into tumors. In PsPD, the tumor transiently enlarges because of massive T-cell accumulation within the tumor. In this case, the peripheral blood lymphocyte count decreased, and the interleukin-6 level was markedly elevated, which was thought to reflect T-cell accumulation in the tumor. These trends in the blood tests may be useful in easily differentiating PsPD from true progressive disease during tarlatamab treatment.

Indexed as

bispecific t-cell engagerimmunotherapypseudoprogressionsmall-cell lung cancertarlatamabt-cell infiltration

Identifiers

PMID41835784
PMCPMC12983044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.